Terns Pharmaceuticals Inc [TERN] stock is trading at $36.58, down -0.05%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TERN shares have gain 7.24% over the last week, with a monthly amount drifted -12.86%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Terns Pharmaceuticals Inc [NASDAQ: TERN] stock has seen the most recent analyst activity on November 04, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $20 for it. Previously, William Blair upgraded its rating to Outperform on November 03, 2025. On October 15, 2025, Truist initiated with a Buy rating and assigned a price target of $20 on the stock. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $15 on September 17, 2025. In a note dated October 31, 2024, Oppenheimer initiated an Outperform rating and provided a target price of $82 on this stock.
Terns Pharmaceuticals Inc [TERN] stock has fluctuated between $1.87 and $48.26 over the past year. Currently, Wall Street analysts expect the stock to reach $55.38 within the next 12 months. Terns Pharmaceuticals Inc [NASDAQ: TERN] shares were valued at $36.58 at the most recent close of the market. An investor can expect a potential return of 51.39% based on the average TERN price forecast.
Analyzing the TERN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.3 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Terns Pharmaceuticals Inc’s Current Ratio is 19.52. As well, the Quick Ratio is 19.52, while the Cash Ratio is 9.79.
Transactions by insiders
Recent insider trading involved Burroughs Amy L., Chief Executive Officer, that happened on Jan 15 ’26 when 68749.0 shares were sold. Director, AMY BURROUGHS completed a deal on Jan 15 ’26 to buy 97915.0 shares. Meanwhile, Chief Executive Officer Burroughs Amy L. sold 71339.0 shares on Jan 05 ’26.
